Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 6;2(2):100089.
doi: 10.1016/j.bneo.2025.100089. eCollection 2025 May.

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms

Leah A Goldberg  1 , James J Yoon  2 , Hannah Johnston  3 , Marta B Davidson  4 , Alexa Siddon  5 , Rory M Shallis  4 , Evan C Chen  6 , Madelyn Burkart  7 , Timothy S Oh  8 , Sunil G Iyer  9 , Ellen Madarang  10 , Chandrasekar Muthiah  11 , Joshua Kassner  12 , Raajit K Rampal  13 , Guru Subramanian Guru Murthy  14 , Terrence Bradley  10 , Yasmin Abaza  8 , Jacqueline S Garcia  6 , Vikas Gupta  4 , Kristen M Pettit  15 , Olatoyosi Odenike  3 , John F Cursio  16 , Anand A Patel  3
Affiliations

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms

Leah A Goldberg et al. Blood Neoplasia. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: R.M.S. reports consultancy fees and honoraria from Gilead Sciences, Inc, Servier, Rigel, and Kura Oncology; and other fees including for steering committee from Servier. V.G. reports consultancy and advisory board fees from 10.13039/100004336Novartis, 10.13039/100017655Incyte, Bristol Myers Squibb (BMS)-10.13039/100006436Celgene, AbbVie, and GlaxoSmithKline (GSK); and research grants from AbbVie and Novartis. E.C.C. reports consultancy fees from AbbVie and Rigel. S.G.I. reports honoraria from Medical Loquix; and membership on an entity’s board of directors or advisory committees in MorphoSys. R.K.R. reports research funding from 10.13039/100017655Incyte Corporation, Stemline Therapeutics, 10.13039/100025208Constellation/10.13039/501100013650MorphoSys, Zentalis, and Ryvu; and consultancy fees from Incyte Corporation, Celgene/BMS, Blueprint, AbbVie, CTI BioPharma, Stemline Therapeutics Galecto, PharmaEssentia, Jubilant, Constellation/MorphoSys, Sierra Oncology/GSK, Protagonist, Cogent, Sumitomo Dainippon, Kartos, Servier, Zentalis, Karyopharm, Disc Medicine, Jazz Pharmaceuticals, Novartis, and Promedior. G.S.G.M. reports advisory board fees from 10.13039/100017239BeiGene, 10.13039/100005564Gilead Sciences/Kite, Pfizer, Autolus, Syndax, and BMS; research funding from 10.13039/100017239BeiGene, 10.13039/100005564Gilead Sciences/Kite, LOXO/Lilly, Zentalis, Schrodinger, and Merck; consultancy fees from Amgen; and speakers bureau fees from Amgen, Rigel, and Stemline. T.B. reports membership on an entity’s board of directors or advisory committees on and speakers bureau fees from Novartis, Geron Corporation, and Gilead. Y.A. reports consultancy fees from Kite/Gilead, Pfizer, Servier, Astellas, Rigel, BMS/Celgene, and Geron; and research funding from ALX Oncology, Biosight, Curis, 10.13039/100004336Novartis, Biomea Fusion, and 10.13039/100006483AbbVie. J.S.G. reports consultancy fees from 10.13039/100006483AbbVie, Genentech, and Servier; research funding from 10.13039/100006483AbbVie, Genentech, Taiho, and Newave; and membership on an entity’s board of directors or advisory committees in Genentech. K.M.P. reports consultancy fees from AbbVie Incyte, PharmaEssentia, Protagonist Therapeutics, and Sierra Oncology; membership on an entity’s board of directors or advisory committees at AbbVie, Merck, GSK, PharmaEssentia, and Protagonist Therapeutics; and research funding from AbbVie, Blueprint Medicines, 10.13039/100002491BMS, Imago, Kura Oncology, and Merck. O.O. reports research funding from 10.13039/100006483AbbVie (Inst), Agios (Inst), Aprea AB (Inst), 10.13039/100013870Astex Pharmaceuticals (Inst), 10.13039/100004325AstraZeneca (Inst), 10.13039/100002491BMS (Inst), 10.13039/100006436Celgene (Inst), 10.13039/100017577CTI BioPharma Corp (Inst), 10.13039/501100022274Daiichi Sankyo (Inst), 10.13039/100017655Incyte (Inst), 10.13039/100005565Janssen Oncology (Inst), and Kartos Therapeutics (Inst); honoraria from AbbVie, Blueprint Medicines, BMS/Celgene (Inst), Celgene, CTI BioPharma, Impact Biomedicines, Kymera, Novartis, Servier, Taiho Pharmaceutical, and Treadwell Therapeutics. A.A.P. reports research funding from 10.13039/100004319Pfizer, Kronos Bio, Sumitomo, 10.13039/100017655Incyte, and Servier; honoraria from AbbVie, BMS, and Sobi. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Survival outcomes in patients with IDH1- or IDH2-mutated MPN-AP/BP. (A) OS in patients with IDH1/2m MPN-AP/BP compared with those with IDH1/2wt MPN-AP/BP. (B) OS in patients with IDH1m MPN-AP/BP compared with those with IDH2m MPN-AP/BP. (C) OS in patients with IDH1/2m MPN-BP compared with those with IDH1/2wt MPN-BP. (D) OS in patients with IDH1/2m MPN-AP/BP based on 1L treatment approach. JAKi, JAK inhibitor.
See this image and copyright information in PMC

References

    1. Patel AA, Odenike O. SOHO state of the art updates and next questions | accelerated phase of MPN: what it is and what to do about it. Clin. Lymphoma Myeloma Leuk. 2023;23(5):303–309. - PubMed
    1. Patel AA, Rampal RK. Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia. Haematologica. 2025;110(4):828–839. - PMC - PubMed
    1. Patel AA, Yoon JJ, Johnston H, et al. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Adv. 2024;8(13):3468–3477. - PMC - PubMed
    1. Patel AA, Odenike O. Genomics of MPN progression. Hematology Am. Soc. Hematol. Educ. Program. 2020;2020(1):440–449. - PMC - PubMed
    1. Norman M, Yamartino K, Gerstein R, et al. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Rev Hematol. 2024;17(11):755–764. - PubMed

LinkOut - more resources